Ascentage Pharma Group International
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Ascentage Pharma Group International (AAPG; 6855.HK), founded in 2009 and headquartered in Suzhou, China, is a clinical-stage global biopharmaceutical company that discovers, develops, and commercializes novel small-molecule therapies targeting apoptosis pathways for cancers, chronic hepatitis B virus, and age-related diseases; it operates primarily in China with clinical trials across the United States, Europe, Australia, and Asia, and maintains offices in Beijing, Shanghai, Guangzhou, Taizhou, Sydney, and Rockville, Maryland. The company's core products include the approved BCR-ABL tyrosine kinase inhibitor olverembatinib (HQP1351; brand name:耐立克), indicated for chronic myeloid leukemia in chronic phase resistant or intolerant to prior TKIs and newly approved for adult Ph+ acute lymphoblastic leukemia patients; the approved Bcl-2 selective inhibitor lisaftoclax (APG-2575; brand name:利生妥), for chronic lymphocytic leukemia and small lymphocytic lymphoma; alrizomadlin (APG-115), an oral MDM2-p53 inhibitor for solid tumors and hematological malignancies; pelcitoclax (APG-1252), a dual Bcl-2/Bcl-xL inhibitor for small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumors, and non-Hodgkin's lymphoma; APG-1387, an IAP inhibitor for advanced solid tumors and HBV; APG-2449, an oral FAK/ROS1/ALK inhibitor; APG-5918, an EED inhibitor; and other pipeline candidates addressing hematologic malignancies such as acute myeloid leukemia, myelodysplastic syndromes, and multiple myeloma. Ascentage Pharma focuses on oncology and hematology segments, serving patients with unmet needs through its innovative pipeline of nine registrational Phase III trials, including FDA- and EMA-cleared studies like GLORA-4 for lisaftoclax plus azacitidine in first-line higher-risk myelodysplastic syndrome. Recent developments include its Nasdaq listing (AAPG) on January 24, 2025, raising $126 million in its U.S. IPO; a July 2025 top-up placement generating $190.1 million in net proceeds; 93% year-over-year olverembatinib sales growth to $30.3 million in H1 2025 with expanded access via 782 pharmacies and hospitals; Takeda equity investment closure of $75 million in June 2024 and a December 2024 option agreement for olverembatinib licensing with $100 million upfront; ongoing global partnerships with AstraZeneca, Merck, Pfizer, Innovent Biologics, and institutions like MD Anderson Cancer Center and Mayo Clinic; and third breakthrough therapy designation for olverembatinib in frontline Ph+ acute lymphoblastic leukemia.
Company News
Ascentage Pharma to Participate in Four Upcoming Investor Conferences
Ascentage Pharma Group International (AAPG) Q2 2026 Earnings Call Transcript
Ascentage Pharma Group International H1 Earnings Call Highlights
Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates
Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up – Still a Buy?
CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer
Wall Street Analysts Predict a 160.09% Upside in Ascentage Pharma Group International - Unsponsored ADR (AAPG): Here's What You Should Know
Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026
How Much Upside is Left in Ascentage Pharma Group International - Unsponsored ADR (AAPG)? Wall Street Analysts Think 152.23%
Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress
Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026
Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026
Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026
Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026
Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026
Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026
Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026